Confronting the Care Delivery Challenges Arising from Precision Medicine

por Kohn, Elise C., Ivy, S. Percy
Publicado 2016

Editorial: New Approaches to Radiation-Therapeutic Agent Cancer Care for Women

por Kunos, Charles A., Kohn, Elise C.
Publicado 2017

STAMP alters the growth of transformed and ovarian cancer cells

por He, Yuanzheng, Blackford, John A, Kohn, Elise C, Simons, S Stoney
Publicado 2010

Ovarian cancer treatment: The end of empiricism?

por Lheureux, Stephanie, Karakasis, Katherine, Kohn, Elise C., Oza, Amit M.
Publicado 2015

Apoptosis is augmented in high-grade serous ovarian cancer by the combined inhibition of Bcl-2/Bcl-xL and PARP

por Yokoyama, Takuhei, Kohn, Elise C., Brill, Ethan, Lee, Jung-Min
Publicado 2017

Proteomics as a Tool for Biomarker Discovery

por Kohn, Elise C., Azad, Nilofer, Annunziata, Christina, Dhamoon, Amit S., Whiteley, Gordon
Publicado 2007

Radiopharmaceuticals for Persistent or Recurrent Uterine Cervix Cancer

por Kunos, Charles A., Capala, Jacek, Kohn, Elise C., Ivy, Susan Percy
Publicado 2019

Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors

por O’Sullivan, Ciara C., Moon, Dominic H., Kohn, Elise C., Lee, Jung-Min
Publicado 2014

The Anti-Apoptotic Activity of BAG3 Is Restricted by Caspases and the Proteasome

por Virador, Victoria M., Davidson, Ben, Czechowicz, Josephine, Mai, Alisha, Kassis, Jareer, Kohn, Elise C.
Publicado 2009

Development of a multiparameter flow cytometric assay as a potential biomarker for homologous recombination deficiency in women with high-grade serous ovarian cancer

por Lee, Jung-Min, Gordon, Nicolas, Trepel, Jane B, Lee, Min-Jung, Yu, Minshu, Kohn, Elise C
Publicado 2015

L-asparaginase inhibits invasive and angiogenic activity and induces autophagy in ovarian cancer

por Yu, Minshu, Henning, Ryan, Walker, Amanda, Kim, Geoffrey, Perroy, Alyssa, Alessandro, Riccardo, Virador, Victoria, Kohn, Elise C
Publicado 2012

Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors

por Annunziata, Christina M., Kohn, Elise C., LoRusso, Patricia, Houston, Nicole D., Coleman, Robert L., Buzoianu, Manuela, Robbie, Gabriel, Lechleider, Robert
Publicado 2012

Comparison of Design, Eligibility, and Outcomes of Neuroendocrine Neoplasm Trials Initiated From 2000 to 2009 vs 2010 to 2020

por Das, Satya, Du, Liping, Lee, Cody L., Arhin, Nina D., Chan, Jennifer A., Kohn, Elise C., Halperin, Daniel M., Berlin, Jordan, LaFerriere, Heather, Singh, Simron, Kunz, Pamela L., Dasari, Arvind
Publicado 2021

Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk

por Lampert, Erika J., Hays, John L., Kohn, Elise C., Annunziata, Christina M., Minasian, Lori, Yu, Minshu, Gordon, Nicolas, Sissung, Tristan M., Chiou, Victoria L., Figg, William D., Houston, Nicole, Lee, Jung-Min
Publicado 2019

Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib

por Jain, Lokesh, Sissung, Tristan M, Danesi, Romano, Kohn, Elise C, Dahut, William L, Kummar, Shivaani, Venzon, David, Liewehr, David, English, Bevin C, Baum, Caitlin E, Yarchoan, Robert, Giaccone, Giuseppe, Venitz, Jürgen, Price, Douglas K, Figg, William D
Publicado 2010

CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olapari...

por Lee, Jung-Min, Trepel, Jane B., Choyke, Peter, Cao, Liang, Sissung, Tristan, Houston, Nicole, Yu, Minshu, Figg, William D., Turkbey, Ismail Baris, Steinberg, Seth M., Lee, Min-Jung, Ivy, S. Percy, Liu, Joyce F., Matulonis, Ursula A., Kohn, Elise C.
Publicado 2015

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker...

por Zimmer, Alexandra S., Nichols, Erin, Cimino-Mathews, Ashley, Peer, Cody, Cao, Liang, Lee, Min-Jung, Kohn, Elise C., Annunziata, Christina M., Lipkowitz, Stanley, Trepel, Jane B., Sharma, Rajni, Mikkilineni, Lekha, Gatti-Mays, Margaret, Figg, William D., Houston, Nicole D., Lee, Jung-Min
Publicado 2019

Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer

por Lee, Jung-Min, Hays, John L., Chiou, Victoria L., Annunziata, Christina M., Swisher, Elizabeth M., Harrell, Maria I., Yu, Minshu, Gordon, Nicolas, Sissung, Tristan M., Ji, Jiuping, Figg, William D., Minasian, Lori, Lipkowitz, Stanley, Wood, Bradford J., Doroshow, James, Kohn, Elise C.
Publicado 2017

Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first in class, proof-of-concept, single arm phase 2...

por Lee, Jung-Min, Nair, Jayakumar, Zimmer, Alexandra, Lipkowitz, Stanley, Annunziata, Christina M., Merino, Maria J., Swisher, Elizabeth M., Harrell, Maria I., Trepel, Jane B., Lee, Min-Jung, Bagheri, Mohammad H., Botesteanu, Dana-Adriana, Steinberg, Seth M., Minasian, Lori, Ekwede, Irene, Kohn, Elise C.
Publicado 2018

Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathw...

por MacKay, Helen J., Levine, Douglas A., Bae-Jump, Victoria L., Bell, Daphne W., McAlpine, Jessica N., Santin, Alessandro, Fleming, Gini F., Mutch, David G., Nephew, Kenneth P., Wentzensen, Nicolas, Goodfellow, Paul J., Dorigo, Oliver, Nijman, Hans W., Broaddus, Russell, Kohn, Elise C.
Publicado 2017